Zinc Oxide
| Evidence Level: L3 | Predicted Indications: 5 |
Table of Contents
Zinc Oxide: From Topical Skin Protectant Use to Acne (Predicted)
One-Sentence Summary
Zinc oxide is a long-established topical mineral compound, widely used as a skin-protectant, astringent, and sunscreen ingredient, though the Evidence Pack does not contain a formal original-indication or MOA record for India. The TxGNN model predicts it may be effective for Acne, currently supported by 0 clinical trials and 7 literature references describing zinc’s antibacterial and anti-inflammatory activity in acne-related skin biology.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in current data (Zinc oxide is a widely known OTC topical skin-protectant/astringent ingredient, but no formal Indian regulatory indication text is on file) |
| Predicted New Indication | Acne (disease) |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L3 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on general pharmacological knowledge, zinc oxide is a topical mineral compound long used in dermatological and cosmetic formulations as a skin protectant, mild astringent, and physical UV-blocking agent, with an established safety history in OTC skin-care products.
Zinc ions are known to exert antibacterial activity against Cutibacterium (Propionibacterium) acnes, anti-inflammatory effects, sebum-regulating properties, and antioxidant activity — mechanisms that are directly relevant to acne pathophysiology. This mechanistic overlap between zinc’s well-characterized dermatological role and the biology of acne provides a plausible rationale for the TxGNN prediction, rather than a purely statistical knowledge-graph artifact.
However, because the Evidence Pack does not include a confirmed original indication or an approved MOA text for this candidate, the rationale above rests on general pharmacological literature (below) rather than a documented approved-label linkage. This should be formally verified before further prioritization.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29193602 | 2018 | Review | Dermatologic Therapy | Reviews zinc’s role in acne treatment as an alternative to antibiotics/retinoids, given the adverse-effect burden of standard therapies |
| 15536660 | 2004 | Cohort (split-face) | Skin Research and Technology | Small clinical assessment of mild inflammatory catamenial acne management |
| 21342155 | 2011 | Review (nanomaterials) | International Journal of Dermatology | Discusses zinc oxide nanoparticles as an investigational treatment for acne vulgaris and other dermatologic conditions |
| 31322532 | 2019 | Formulation study | Georgian Medical News | Develops zinc-containing powder cosmetic formulations for acne care/prevention |
| 29284390 | 2018 | Preclinical/material engineering | Current Medicinal Chemistry | Reviews antimicrobial nanoparticle-functionalized textiles (including zinc-based materials) for skin/wound care such as acne |
| 36888703 | 2023 | Preclinical/device development | Science Advances | Zinc-porphyrin metal-organic nanoparticle microneedle patch for ultrasound-triggered antibacterial acne treatment |
| 41033952 | 2025 | Preclinical/mechanism | Science Bulletin | ZnO-based piezoelectric heterojunction selectively modulates skin microbiota via C. acnes redox activity |
India Market Information
No marketing authorizations are currently on file for this candidate (India market status: Not Marketed, 0 registrations recorded).
Safety Considerations
Please refer to the package insert for safety information. No approved Indian labeling currently exists for this candidate, and warnings, contraindications, and drug-interaction data are not yet available in the Evidence Pack.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic rationale for zinc oxide in acne is biologically plausible and supported by review-level and small clinical literature, but no clinical trials exist for this indication, the drug is not currently marketed in India, and safety-critical data (label warnings/contraindications, MOA) are flagged as blocking gaps.
To proceed, the following is needed:
- Official label warnings and contraindications (Data Gap DG001 — Blocking; required before any S1 safety screening)
- Confirmed mechanism of action from an authoritative source such as DrugBank (Data Gap DG002 — High priority)
- Confirmed original approved indication(s) for zinc oxide, if any, in the Indian regulatory context
- Identification or design of controlled (ideally RCT-level) clinical trials evaluating topical zinc oxide specifically for acne
- Route-of-administration compatibility assessment (currently marked “pending”) to confirm topical formulation feasibility
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.